Mark Sullivan

Mark Sullivan, President of Regulated Industries at Salesforce, shares insights on AI adoption in life sciences. He discusses the shift from experimentation to tangible impacts, emphasizing the importance of AI for augmenting rather than replacing the workforce. Sullivan highlights challenges with inaccurate agents and the need for high-quality data. He illustrates how agents can enhance patient engagement and streamline clinical trials while stressing the necessity of trust and governance in deploying these technologies effectively.